ELDN - NASDAQ
Eledon Pharmaceuticals, Inc.
$3.53
+6.0%Eledon Pharmaceuticals, Inc., clinical stage biopharmaceutical company, focuses on developing medicines for the patients living with autoimmune disease and amyotrophic lateral sclerosis (ALS), and requiring an organ or cell-based transplant. Its lead product candidate includes AT-1501, a humanized monoclonal antibody to target CD40 Ligand that is a molecule expressed on the surface of human immune system T cells, which is in Phase 2a clinical trials for the treatment of ALS, and Phase 2 clinical trials in islet cell transplantation for the treatment of type 1 diabetes. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.
At a Glance
Live SnapshotNo Revenue Data
ELDN has not reported any revenue values in the available annual periods.
Eledon Pharmaceuticals, Inc. Profit Bridge
Profitability Analysis
Eledon Pharmaceuticals, Inc. Income Statement
ELDN • NASDAQ
| Eledon Pharmaceuticals, Inc. Income Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
REVENUE | ||||||||||||||
GROSS PROFIT | ||||||||||||||
(0.0) | (359K) | (374K) | (373K) | (195K) | (183K) | (182K) | (11K) | (22K) | (35K) | (109K) | (58.0) | (0.0) | (0.0) | |
0.0 | -359K | -374K | -373K | -195K | -183K | -182K | -11K | -22K | -35K | -109K | -58.0 | 0.0 | 0.0 | |
OPERATING INCOME | ||||||||||||||
(83.3M) | (70.2M) | (42.6M) | (39.4M) | (36.7M) | (13.1M) | (14.2M) | (14.1M) | (13.1M) | (38.1M) | (45.3M) | (23.5M) | (15.7M) | (9.6M) | |
(17M) | (18.3M) | (12.3M) | (12.3M) | (12.9M) | (7M) | (6.1M) | (7.2M) | (11.1M) | (13.1M) | (12.6M) | (8.9M) | (3.5M) | (2.3M) | |
(66.3M) | (52M) | (30.3M) | (27.1M) | (23.7M) | (6.1M) | (8.1M) | (6.8M) | (2M) | (25M) | (32.6M) | (14.6M) | (12.2M) | (7.4M) | |
-83.3M | -70.6M | -43M | -39.8M | -36.9M | -13.3M | -16.1M | -14.1M | -13.1M | -38.1M | -45.3M | -23.5M | -15.7M | -9.6M | |
PRE-TAX INCOME | ||||||||||||||
(0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (174K) | (0.0) | (0.0) | (0.0) | |
(0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (40K) | -5K | (5K) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
37.7M | 34.8M | -73.5M | -48.2M | 7K | -9.9M | 40K | -5K | 5K | -527K | 174K | 166K | 24K | 0.0 | |
-45.6M | -35.8M | -116.5M | -88M | -36.9M | -23.2M | -16M | -14.1M | -13.1M | -38M | -45.1M | -23.3M | -15.7M | -9.6M | |
NET INCOME | ||||||||||||||
(35K) | (431K) | (0.0) | (0.0) | -2.4M | -404K | (1.9M) | -5K | (0.0) | (136K) | (0.0) | -187K | (0.0) | (0.0) | |
-45.6M | -36.2M | -116.5M | -88M | -34.5M | -22.8M | -17.9M | -14.1M | -13.1M | -38M | -45.1M | -23.3M | -15.7M | -9.6M |
SEC Filings
ELDN - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
10-Q 10-Q 2026 Q1 Q1 | May 13, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 13, 2026 | May 13, 2026 | 2026 | |
S-3 S-3 N/A | May 01, 2026 | May 01, 2026 | ||
DEF 14A DEF 14A 2026 N/A | April 30, 2026 | June 18, 2026 | 2026 | |
10-K 10-K 2025 FY FY | March 19, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | March 19, 2026 | March 19, 2026 | 2026 | |
8-K 8-K 2025 N/A | January 02, 2026 | December 30, 2025 | 2025 | |
8-K 8-K 2025 N/A | November 14, 2025 | November 14, 2025 | 2025 | |
10-Q 10-Q 2025 Q3 Q3 | November 14, 2025 | September 30, 2025 | 2025 | |
8-K 8-K 2025 N/A | November 13, 2025 | November 12, 2025 | 2025 |
Related Guides
Continue your ELDN research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.